医療業界を専門とする米国の調査会社 Arrowhead Publishers (本社：ミネソタ州)
では、注射型ドラッグデリバリーに関する市場影響と業界動向について詳細に調査分析した調査報告書 "Injectable Drug
Delivery: Market Impact and Industry Trends" を発行いたしました。
As competition in the pharmaceutical marketplace grows, companies are
increasingly looking towards the drug delivery industry to maximize revenues
and combat generic competitors. The search for more efficient drug delivery
systems is also being driven by the rise in patient demand, healthcare and
pharma cost containment, as much as by medical and technological advances.
The global market for drug delivery technology is worth in excess of US$25
billion in sales. Given its predicted annual growth of 15 percent, the market
represents a considerable business opportunity, which has been reflected in
the increasing number of drug delivery specialists. According to Arrowhead
Publishers' new report entitled Injectable Drug Delivery: Market Impact and
Industry Trends, injectables currently account for an estimated 15 percent of
the global drug delivery market, with the US being the leading individual
market.
Key features of this report:
Overview of the drug delivery environment
In-depth analysis of the injectable drug delivery industry, including main
types and main marketed systems, and their advantages and disadvantages
Comprehensive facts and figures for the injectable drug delivery market,
including main players and key therapeutic areas
Future trends in the injectables marketplace, shaped by medical and
technological advances as much as demographic and epidemiological changes and
industry needs
Outlook for the injectable drug delivery technology
Who should buy this report?
Stakeholders in the injectable drug delivery market
Companies interested in understanding the impact and implications of
securing the correct injectable drug delivery technology in terms of product
placement, lifecycle management and competition in the marketplace
Companies interested in understanding future opportunities in the
injectable drug delivery sector provided by a combination of factors,
including changing public health needs
Pharma/biotech companies wishing to identify potential injectable drug
delivery areas for partnerships and collaboration in order to examine a
variety of profit maximization strategies
Table of Contents
1. Executive Summary
2. Introduction to Drug Delivery
2.1. Drug Delivery Technologies and Pharmaceutical Revenues
2.2. Drug Delivery Technologies and Wider Healthcare Market
3. Overview of Injectable Drug Delivery
3.1. Advantages and Disadvantages of Injectable Delivery
3.2. Types of Injectable Drug Delivery
4. Main Categories of Marketed Injectable Drug Delivery Systems
4.1. Sustained Release Injectable Systems
4.2. Advantages of Injectable Sustained-Release Formulations
4.3. Liposomal Systems
4.4. Advantages of Injectable Liposomal Formulations
4.5. Needleless Systems
4.6. Advantages of Injectable Needleless Formulations
5. Injectable Drug Delivery Market - Facts and Figures
5.1. Injectable Drug Delivery Market Overview
5.2. Key Therapeutic Areas for Injectable Drug Delivery
5.3. Acromegaly
5.4. Age-Related Macular Degeneration
5.5. Crohn' s Disease
5.6. Diabetes
5.7. Hepatitis C
5.8. Multiple Sclerosis
5.9. Neutropenia
5.10. Oncology
5.11. Pain
5.12. Psoriasis
5.13. Rheumatoid Arthritis
6. Drug Classes Appropriate for Injectable Drug Delivery
7. Main Players and Partnerships in the Injectable Drug Delivery Market
8. Key Company Involvement in the Field of Injectable Drug Delivery
8.1. Alkermes
8.2. ALZA
8.3. Aradigm
8.4. Bioject
8.5. Enzon
8.6. Ethypharm
8.7. MacroMed
8.8. Nektar Therapeutics
8.9. QLT
8.10. SkyePharma
9. Sales of Products Utilizing Injectable Drug Delivery Technology
10. Profiles of Key Products Using Injectable Drug Delivery Technology
10.1. Neulasta (Nektar/Amgen)
10.2. PEGASYS (Roche/Nektar)
10.3. PEG-Intron (Schering-Plough)
10.4. Risperdal Consta
10.5. Sandostatin (Novartis)
10.6. Vivitrol (Alkermes)
11. Recent Launches and Approvals in the Field of Injectable Drug Delivery
11.1. August 2006
11.2. July 2006
11.3. May 2006
11.4. April 2006
11.5. February 2006
11.6. January 2006
12. Current Research and Profiles of Key Pipeline Products in the Field of Injectable Drug Delivery
12.1. Cimzia (Nektar)
12.2. Mircera/CERA (Nektar)
12.3. Paliperidone Palmitate (Johnson & Johnson)
12.4. Intraject Sumatriptan (Zogenix)
13. Future of Injectable Drug Delivery Technology
13.1. Emerging Injectable Drug Delivery Technologies
13.2. Emerging Therapeutic Targets for Injectable Drug Delivery
13.3. Future Therapeutic Targets for Injectable Drug Delivery
13.4. New Technology and the Injectable Drug Delivery Market
13.5. New Threats to the Injectable Drug Delivery Market
13.6. New Healthcare Needs and the Injectable Drug Delivery
14. Outlook for Injectable Drug Delivery Technology
